Additionally, we performed comprehensive drug sensitivity profiling in HCC, revealing that HCC patients with high G6PC1 expression exhibited greater sensitivity to axitinib, gemcitabine, irinotecan, cytarabine, sorafenib, and I-BET-762 (Figure 9C). The gene discussed is G6PC1; the disease is hepatocellular carcinoma.